Dandrit - ny analyse fra Nordic Bio Investor
-
valueringen er ensbetydende med et target på cirka 18 dollar.... den handles pt omkring 5 (fem) dollar. Og det er ikke et target på 1 års sigt, men derimod et bud på værdien efter 3. kvartal i år (under forudsætning af at Fase III forsøget igangsættes som forventet af selskabet)
ekstraktet siger:
We are estimating an enterprise valuation of 171 million dollars, compared to the current market cap of 38 million dollars. However in order to unlock the enterprise value upside, DanDrit needs to execute on its objectives during the coming months by getting its pivotal phase III 174 patients trial underway in Italy and begin enrolling patients. We are very confident this will happen during the current quarter. Secondly the myTomorrows Compassionate Use program needs to begin enrolling patients in Europe, also during this quarter. We are also confident in this taking place.
http://www.otcmarkets.com/financialReportViewer?symbol=DDRT&id=141830
det er stadigvæk ikke vildt let at handle aktien - men det kan dog gøres via Nordnets dealer-bord...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind